OBJECTIVE: The development of pathogenic antineutrophil cytoplasmic antibodies (ANCAs) can result in systemic small vessel vasculitis. However, the breakdown in immune tolerance that results in the induction and persistence of ANCAs is not well understood. We undertook this study to test our hypothesis that abnormal T cell regulation is central to disease pathogenesis in patients with ANCA-associated vasculitis (AAV). METHODS: Peripheral blood samples were obtained from 62 patients with AAV and 19 healthy controls for flow cytometric analysis of CD4+ T cell populations. Functional T cell studies were performed with fluorescence-activated cell sorted CD4+ T cell populations stimulated with anti-CD3/anti-CD28. RESULTS: We demonstrated two separate abnormalities in T cell regulation in patients with AAV. First, we showed that the Treg cell frequency was increased in the peripheral blood of patients with active disease, but Treg cells from patients with AAV had decreased suppressive function. Treg cells from patients with active disease disproportionately used a FoxP3 isoform lacking exon 2, which might alter Treg cell function. Second, we identified a CD4+ T cell population with increased frequency that was resistant to Treg cell suppression, produced proinflammatory cytokines, and was antigen experienced. CONCLUSION: AAV is associated with disruption of the suppressive Treg cell network and with increased frequency of a distinct proinflammatory effector T cell subset that comprises the majority of peripheral CD4+ T cells.
OBJECTIVE: The development of pathogenic antineutrophil cytoplasmic antibodies (ANCAs) can result in systemic small vessel vasculitis. However, the breakdown in immune tolerance that results in the induction and persistence of ANCAs is not well understood. We undertook this study to test our hypothesis that abnormal T cell regulation is central to disease pathogenesis in patients with ANCA-associated vasculitis (AAV). METHODS: Peripheral blood samples were obtained from 62 patients with AAV and 19 healthy controls for flow cytometric analysis of CD4+ T cell populations. Functional T cell studies were performed with fluorescence-activated cell sorted CD4+ T cell populations stimulated with anti-CD3/anti-CD28. RESULTS: We demonstrated two separate abnormalities in T cell regulation in patients with AAV. First, we showed that the Treg cell frequency was increased in the peripheral blood of patients with active disease, but Treg cells from patients with AAV had decreased suppressive function. Treg cells from patients with active disease disproportionately used a FoxP3 isoform lacking exon 2, which might alter Treg cell function. Second, we identified a CD4+ T cell population with increased frequency that was resistant to Treg cell suppression, produced proinflammatory cytokines, and was antigen experienced. CONCLUSION: AAV is associated with disruption of the suppressive Treg cell network and with increased frequency of a distinct proinflammatory effector T cell subset that comprises the majority of peripheral CD4+ T cells.
Authors: James D Lord; Karine Valliant-Saunders; Hejin Hahn; Richard C Thirlby; Steven F Ziegler Journal: Dig Dis Sci Date: 2012-06-27 Impact factor: 3.199
Authors: J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg Journal: Arthritis Rheum Date: 1994-02
Authors: C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs Journal: Nat Genet Date: 2001-01 Impact factor: 38.330
Authors: M E Christine Lutsiak; Roshanak T Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Todd M Brusko; Clive H Wasserfall; Michael J Clare-Salzler; Desmond A Schatz; Mark A Atkinson Journal: Diabetes Date: 2005-05 Impact factor: 9.461
Authors: Sarah E Allan; Laura Passerini; Rosa Bacchetta; Natasha Crellin; Minyue Dai; Paul C Orban; Steven F Ziegler; Maria Grazia Roncarolo; Megan K Levings Journal: J Clin Invest Date: 2005-10-06 Impact factor: 14.808
Authors: Qizhi Tang; Kammi J Henriksen; Mingying Bi; Erik B Finger; Greg Szot; Jianqin Ye; Emma L Masteller; Hugh McDevitt; Mark Bonyhadi; Jeffrey A Bluestone Journal: J Exp Med Date: 2004-06-07 Impact factor: 14.307
Authors: Y Hamano; M Abe; S Matsuoka; D Zhang; Y Kondo; Y Kagami; A Ishigami; N Maruyama; Y Tsuruta; W Yumura; K Suzuki Journal: Clin Exp Immunol Date: 2014-07 Impact factor: 4.330
Authors: Luis Felipe Flores-Suárez; Marco A Alba; Heidegger Mateos-Toledo; Natllely Ruiz Journal: Curr Rheumatol Rep Date: 2017-09 Impact factor: 4.592
Authors: Chie Miyabe; Yoshishige Miyabe; Klemen Strle; Nancy D Kim; John H Stone; Andrew D Luster; Sebastian Unizony Journal: Ann Rheum Dis Date: 2016-12-07 Impact factor: 19.103
Authors: Dragana Odobasic; Virginie Oudin; Kenji Ito; Poh-Yi Gan; A Richard Kitching; Stephen R Holdsworth Journal: J Am Soc Nephrol Date: 2019-08-23 Impact factor: 10.121
Authors: Britta E Jones; Carolina A Herrera; Christian Agosto-Burgos; Joshua Starmer; William A Bass; Caroline J Poulton; Lauren Blazek; Candace D Henderson; Yichun Hu; Susan L Hogan; Peiqi Hu; Hong Xiao; Eveline Y Wu; Dhruti P Chen; J Charles Jennette; Meghan E Free; Ronald J Falk; Dominic J Ciavatta Journal: Kidney Int Date: 2020-05-21 Impact factor: 10.612